Drug Profile


Alternative Names: 06-BG; Alkylade; BG; KRX 0402; NSC 638037; O6-benzylguanine

Latest Information Update: 03 Feb 2011

Price : $50

At a glance

  • Originator National Institutes of Health (USA); The Pennsylvania State University
  • Developer ACCESS Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Chemosensitisers; Hypoxanthines; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain cancer; Glioblastoma; Glioma; Multiple myeloma; Sarcoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
  • 10 Oct 2002 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top